Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 10/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20754812 | 0.91 | APLNR (0.49) | APLNRMAPTPKMTAS2R14CXCR3 | |
| SCHEMBL23033072 | 0.89 | APLNR (0.44) | APLNRMAPTPKMTAS2R14CXCR3 | |
| SCHEMBL20754872 | 0.88 | APLNR (0.51) | APLNRMAPTPKMTAS2R14CXCR3 | |
| SCHEMBL20754483 | 0.87 | APLNR (0.47) | APLNRMAPTPKMTAS2R14CXCR3 | |
| SCHEMBL23852214 | 0.86 | APLNR (0.51) | APLNRMAPTPKMTAS2R14CXCR3 | |
| SCHEMBL20755005 | 0.86 | APLNR (0.51) | APLNRMAPTPKMTAS2R14CXCR3 | |
| SCHEMBL20757301 | 0.86 | APLNR (0.46) | APLNRMAPTPKMTAS2R14CXCR3 | |
| SCHEMBL20757668 | 0.86 | APLNR (0.46) | APLNRMAPTPKMTAS2R14CXCR3 | |
| SCHEMBL23012267 | 0.85 | APLNR (0.50) | APLNRMAPTPKMTAS2R14CXCR3 | |
| SCHEMBL23033161 | 0.85 | APLNR (0.45) | APLNRMAPTPKMTAS2R14CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012392-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-08 | — | — | US | disclosed |
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, PYCARD | APLNR 2957/4885MAPT 2084/4885PKM 1695/4885 |
| US-12012392-B2 | Sulfonamide carboxamide compounds | NLRP3, PYCARD, NOD1 | APLNR 3254/4885MAPT 2011/4885PKM 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.